US · DNTH
Dianthus Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10036
- Website
- dianthustx.com
Price · as of 2024-12-31
$87.42
Market cap 2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $39.09 | -55.28% |
| Intrinsic Value(DCF) | $13.53 | -84.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $256.00 | ||||
| 2019 | $190.88 | ||||
| 2020 | $208.48 | ||||
| 2021 | $44.64 | ||||
| 2022 | $12.00 | $181.42 | $10.35 | $0.00 | $0.00 |
| 2023 | $25.13 | $27.19 | $21.55 | $0.00 | $384.00 |
| 2024 | $24.03 | $39.09 | $6.77 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Dianthus Therapeutics, Inc.'s (DNTH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $39.09
- Current price
- $87.42
- AI upside
- -55.28%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$13.53
-84.52% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DNTH | Dianthus Therapeutics, In… | $87.42 | 2B | -55% | -85% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| ANAB | AnaptysBio, Inc. | $55.05 | 1.52B | -23% | +23,485% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| ELVN | Enliven Therapeutics, Inc… | $29.69 | 1.76B | — | — | — | — | -11.10 | 3.19 | — | -6.48 | — | 3.19 | 0.00% | — | — | -32.04% | 1991.13% | -29.79% | 0.00 | — | 19.99 | 19.69 | 1.19 | -597.00% | — | 1924.00% | -7.41% | -4.60 | 1394.71% | 0.00% | 0.00% | 2.46% | -6.46 | -9.22 | — | 36.28 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| TSHA | Taysha Gene Therapies, In… | $4.53 | 1.24B | +543% | -85% | — | +183% | -4.90 | 6.12 | 52.53 | -4.11 | — | 6.12 | 100.00% | -1097.55% | -1071.62% | -121.94% | 1496.02% | -53.62% | 0.88 | -896.66 | 5.42 | 5.30 | 0.86 | -6284.00% | -4607.00% | 151.00% | -18.64% | -3.10 | 1334.73% | 0.00% | 0.00% | 0.00% | -3.96 | -4.43 | 43.43 | -3.26 |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
- CEO
- Marino Garcia
- Employees
- 78
- Beta
- 1.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($13.53 ÷ $87.42) − 1 = -84.52% (DCF, example).